Dermatol. praxi. 2013;7(3):113-119 [Prakt. lékáren. 2013; 9(2): 59-63]
Local therapy of psoriasis
- Kožní oddělení nemocnice v Jihlavě
Psoriasis is a chronic, inflammatory hyperproliferative disease of the skin, scalp, nails and joints. It belongs to a group of papulosquamosus
skin disorders and is presented by a variety of clinical presentations. Basic treatment is a local therapy, another treatment options
are phototherapy and systemic therapy. In this article, local therapy is described. It is a ground option for mild and moderate psoriasis,
a complementary one for a severy psoriasis. A first line local therapy includes topical corticosteroids and D3 derivates; tars, ichtamol,
cignolin, baths and local imunomodulators are also useful. Many completely new therapeutics are developed and proved.
Keywords: psoriasis, local therapy, corticosteroids, vitamin D3 derivates
Published: November 1, 2013 Show citation
References
- Bowcock AM. Genetics of psoriasis: the potential impact on new terapies, J Am Acad Dermatol 2003; 49: 851-856.
Go to original source... 
Go to PubMed... - Vašků V. Etiopatogeneze. In: Benáková N. Terapie obecně. In: Benáková N, Ettler K, Štork J, Vašků V. Psoriáza nejen pro praxi. Praha/Kroměříž: Triton 2007: 47-58.
- Menter A, Korman NJ, Elmets CA, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60(4): 643-659. Go to original source... Go to PubMed...
- Papp KA, et al. Canadian Guidelines for the Management of Plaque Psoriasis 2009, dostupné na http://www.dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf.
- Benáková N. Terapie obecně. In: Benáková N, Ettler K, Štork J, Vašků V. Psoriáza nejen pro praxi. Praha/Kroměříž: Triton 2007: 59-69.
- Benáková N. Lokální terapie. In: Benáková N.: Terapie obecně. In: Benáková N, Ettler K, Štork J, Vašků V. Psoriáza nejen pro praxi. Praha/Kroměříž: Triton 2007: 71-99.
- van de Kerkhof PC, Barker J, Griffiths CE, et al. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008; 22: 859-870. Go to original source... Go to PubMed...
- Fogh K, Kragbale K. Vitamin D3 analogues. Dermatol Ther 1999; 11: 20-31.
- Kerkhof Van de PCM, Peuter de R, Jansen JP. Mixed treatment comparison of a two-compound formulation product containing calcipotriol and bethamethasone dipropionate with other topical treatment in psoriasis vulgaris. Current Medical Research and Opinion 2011; 27: 225-238. Go to original source... Go to PubMed...
- Kragbale Austad J, Barnes L, et al. Efficacy results of 52week, randomised, double-blind safety study of calcipotriol/bethamethasone dipropionate two-compound product in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-326. Go to original source... Go to PubMed...
- De Prost Y. New topical imunological treatments for psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 80-82. Go to original source...
- Benáková N. Lokální léčba psoriázy I: psoriasis vulgaris. Doporučené postupy České dermatologické společnosti ČLS JEP. Čes-slov Derm 2012; 87(1): XXIV-XXXII.
- Chiricozzi A, Chimenti S. Effective Topical Agents and Emerging Perspectives in the Treatment of Psoriasis. Expert Rev Dermatol 2012; 7(3): 283-293. Go to original source...
- Murray PJ. The JAK-STAT signaling pathway: input and output integration. J. Immunol 2007; 178(5): 2623-2629. Go to original source... Go to PubMed...
- Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem Biophys Res Commun 1999; 262(1): 14-19. Go to original source... Go to PubMed...
- Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis 2012. J. Am. Acad. Dermatol. (Epub ahead of print).
- Muramoto K, Goto M, Inoue Y, et al. E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 2010; 335(1): 23-31. Go to original source... Go to PubMed...
- Goto M, Chow J, Muramoto K, et al. E6201 [(3S, 4R, 5Z, 8S, 9S, 11E)-14-(ethylamino)-8, 9, 16-trihydroxy-3,4-dimethyl-3,4, 9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 2009; 331(2): 485-495. Go to original source... Go to PubMed...